- Home
- BIP vs RPRX Comparison
BIP vs RPRX Comparison
Compare BIP & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BIP | RPRX |
|---|---|---|
| Founded | 2007 | 1996 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.3B | 19.4B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | BIP | RPRX |
|---|---|---|
| Price | $38.00 | $45.16 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $37.67 | ★ $47.75 |
| AVG Volume (30 Days) | 708.4K | ★ 3.6M |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | ★ 4.78% | 2.08% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.78 |
| Revenue | N/A | ★ $2,378,193,000.00 |
| Revenue This Year | N/A | $39.10 |
| Revenue Next Year | $7.61 | $5.02 |
| P/E Ratio | $39.22 | ★ $25.38 |
| Revenue Growth | N/A | ★ 5.06 |
| 52 Week Low | $25.72 | $29.66 |
| 52 Week High | $39.85 | $46.14 |
Technical Indicators
Market Signals| Indicator | BIP | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 62.35 | 72.73 |
| Support Level | $36.34 | $42.50 |
| Resistance Level | $39.12 | $46.14 |
| Average True Range (ATR) | 0.82 | 1.01 |
| MACD | 0.05 | 0.14 |
| Stochastic Oscillator | 54.26 | 80.80 |
Price Performance
Historical ComparisonAbout BIP Brookfield Infrastructure Partners LP
Brookfield Infrastructure Partners LP is a Bermuda exempted limited partnership that owns and operates quality, long-life assets that generate stable cash flows, by virtue of barriers to entry or other characteristics that tend to appreciate in value over time. It focuses on acquiring infrastructure assets that have low maintenance capital costs and high barriers to entry. The company's segments consist of Utilities, Transport, Midstream, and Data. Geographically, it generates maximum revenue from USA and also has a presence in Australia, Colombia, United Kingdom, Brazil, United States of America, Chile, Peru, and other countries.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.